Lixte Biotechnology to Present Key Advantages of Novel Cancer Drug Candidate LB-100 at the Sidoti Virtual Microcap Conference...
May 04 2021 - 4:30PM
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage
drug discovery company developing pharmacologically active drugs
for use in cancer treatment, will participate in the Sidoti &
Company LLC Virtual Microcap Conference being held May 19-20, 2021.
Lixte Founder and CEO John S. Kovach, M.D. will present on
Thursday, May 20 at 12:15 p.m. ET. Investors may attend Lixte’s
virtual presentation by visiting the conference registration
webpage.
“During my presentation at the Sidoti
conference, I will focus on the key advantages of our lead compound
LB-100,” said Dr. Kovach. “At present we are not aware of any
clinical competition for LB-100, and we benefit from a broad,
high-value IP asset portfolio. The potential market value for our
product is very large as many preclinical studies by outstanding
independent investigators indicate that LB-100 appears to enhance
the efficacy of chemotherapy, radiotherapy and immunotherapy.”
Lixte’s product pipeline presently includes
three clinical studies and one pharmacology study of LB-100 for
four of the most aggressive cancers: myelodysplastic (MDS)
syndromes, advanced soft tissue sarcomas (ASTS), small cell lung
cancer (SCLC), and glioblastoma multiforme (GBM). The total market
for these cancer targets exceeds $5 billion.
About Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings, Inc. (Nasdaq:LIXT)
is a clinical-stage pharmaceutical company dedicated to discovering
drugs for more effective treatments for many forms of cancer and
other serious common diseases. A major driver of cancer is defects
in the switches that turn the biochemical pathways in cells on and
off. Most cancer research over the past 30 years has focused on the
“on” switches because the “off” switches, especially the master
“off” switch protein phosphatase (PP2A), were believed to cause
intolerable toxicity in patients. Lixte has achieved a breakthrough
with its novel, first-in-class lead compound, PP2A inhibitor
LB-100, by demonstrating that it is readily tolerated in cancer
patients at doses associated with anti-cancer activity. This
innovative approach encourages cancer cells, damaged by chemo or
other cancer therapies, to continue to replicate before repairing
the damage, leading to the more efficient death and elimination of
those cells from the body. Lixte has partnered with top
medical institutions and leading academic research centers to
advance the clinical development of its compounds. The LB-100
compound, of which there are no competitors known to Lixte, is
being tested in three clinical cancer treatment studies with others
in planning. lixte.com
Forward-Looking Statements
This announcement contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, and Section 21E of the Securities Exchange
Act of 1934. For example, statements regarding the Company's
financial position, business strategy and other plans and
objectives for future operations, and assumptions and predictions
about future product demand, supply, manufacturing, costs,
marketing and pricing factors are all forward-looking statements.
These statements are generally accompanied by words such as
"intend," anticipate," "believe," "estimate," "potential(ly),"
"continue," "forecast," "predict," "plan," "may," "will," "could,"
"would," "should," "expect" or the negative of such terms or other
comparable terminology. The Company believes that the assumptions
and expectations reflected in such forward-looking statements are
reasonable, based on information available to it on the date
hereof, but the Company cannot provide assurances that these
assumptions and expectations will prove to have been correct or
that the Company will take any action that the Company may
presently be planning. However, these forward-looking statements
are inherently subject to known and unknown risks and
uncertainties. Actual results or experience may differ materially
from those expected or anticipated in the forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, regulatory policies,
available cash, research results, competition from other similar
businesses, and market and general economic factors. This
discussion should be read in conjunction with the Company's filings
with the United States Securities and Exchange Commission at
sec.gov/edgar.shtml.
Lixte Contact:info@lixte.comGeneral Phone:
(631) 830-7092Investor Phone: (888) 289-5533
Lixte Biotechnology (NASDAQ:LIXT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lixte Biotechnology (NASDAQ:LIXT)
Historical Stock Chart
From Apr 2023 to Apr 2024